GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Henlius Biotech Inc (HKSE:02696) » Definitions » Shares Outstanding (EOP)

Shanghai Henlius Biotech (HKSE:02696) Shares Outstanding (EOP) : 543 Mil (As of Jun. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Shanghai Henlius Biotech Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Shanghai Henlius Biotech's shares outstanding for the quarter that ended in Jun. 2024 was 543 Mil.

Shanghai Henlius Biotech's quarterly shares outstanding stayed the same from Dec. 2023 (543 Mil) to Jun. 2024 (543 Mil).

Shanghai Henlius Biotech's annual shares outstanding stayed the same from Dec. 2022 (543 Mil) to Dec. 2023 (543 Mil).


Shanghai Henlius Biotech Shares Outstanding (EOP) Historical Data

The historical data trend for Shanghai Henlius Biotech's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Henlius Biotech Shares Outstanding (EOP) Chart

Shanghai Henlius Biotech Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shares Outstanding (EOP)
Get a 7-Day Free Trial 543.50 543.50 543.50 543.50 543.50

Shanghai Henlius Biotech Quarterly Data
Dec17 Mar18 Jun18 Dec18 Mar19 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23 Jun24
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 543.50 543.50 543.50 543.50 543.50

Competitive Comparison of Shanghai Henlius Biotech's Shares Outstanding (EOP)

For the Biotechnology subindustry, Shanghai Henlius Biotech's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Henlius Biotech's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Henlius Biotech's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Shanghai Henlius Biotech's Shares Outstanding (EOP) falls into.



Shanghai Henlius Biotech Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Shanghai Henlius Biotech  (HKSE:02696) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Shanghai Henlius Biotech Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Shanghai Henlius Biotech's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Henlius Biotech Business Description

Traded in Other Exchanges
N/A
Address
B8 Building, No. 188 Yizhou Road, 11th Floor, Xuhui District, Shanghai, CHN, 200233
Shanghai Henlius Biotech Inc is a biopharmaceutical company in China with the vision to offer affordable and innovative biologics for patients with a focus on oncology and autoimmune diseases. The Group is engaged in biopharmaceutical R&D, biopharmaceutical services, and biopharmaceutical production and sales. It operates in Mainland China and Overseas. The company products include HLX01 Rituximab, HLX02(trastuzumab), and others.
Executives
Qatar Investment Authority 2201 Interest of corporation controlled by you
Fosun Industrial Co., Limited 2101 Beneficial owner
Shanghai Fosun Pharmaceutical (group) Co., Ltd. 2201 Interest of corporation controlled by you
Fosun Holdings Limited 2201 Interest of corporation controlled by you
Fosun International Holdings Ltd. 2201 Interest of corporation controlled by you
Fosun International Limited 2201 Interest of corporation controlled by you
Guo Guangchang 2201 Interest of corporation controlled by you
Shanghai Fosun High Technology (group) Co., Ltd. 2201 Interest of corporation controlled by you
Liu Scott Shi-kau 2201 Interest of corporation controlled by you
Jiang Wei-dong 2201 Interest of corporation controlled by you
Henlius Biopharmaceuticals, Inc. 2101 Beneficial owner

Shanghai Henlius Biotech Headlines

No Headlines